Posted by Michael Wonder on 09 Feb 2023
EMA confirms acceptance of application for AVT04, a proposed biosimilar to Stelara (ustekinumab)
9 February 2023 - EMA opinion on AVT04 could come as soon as the second half of 2023.
Alvotech and STADA Arzneimittel today announced that the EMA has accepted a marketing authorisation application for AVT04, Alvotech’s proposed biosimilar to Stelara (ustekinumab).
